OP0222 Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 104 weeks results from a phase 3 trial, future 2

Abstract

BackgroundSecukinumab significantly improved the signs and symptoms of psoriatic arthritis (PsA) over 52 weeks (wks) in FUTURE 2 study (NCT01752634).1,2ObjectivesTo present longer-term (104 wks) efficacy and safety data of secukinumab...